Please Wait
Applying Filters...
menu
    • menu
    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Rusan Pharma: Over 30 years of specializing in the treatment of Addiction and Pain Management.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Sharp is a global leader in pharmaceutical packaging and clinical trial supply services.

    Virtual Booth

    Contact Supplier

    Aspen API. More than just an API.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Savolitinib

    DEVELOPMENTS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    2D Structure
    Also known as: Volitinib, 1313725-88-0, Azd-6094, Hmpl-504, Azd6094, Savolitinib [inn]
    Molecular Formula
    C17H15N9
    Molecular Weight
    345.4  g/mol
    InChI Key
    XYDNMOZJKOGZLS-NSHDSACASA-N
    FDA UNII
    2A2DA6857R
    Savolitinib is an orally bioavailable inhibitor of the c-Met receptor tyrosine kinase with potential antineoplastic activity. Savolitinib selectively binds to and inhibits the activation of c-Met in an ATP-competitive manner, and disrupts c-Met signal transduction pathways. This may result in cell growth inhibition in tumors that overexpress the c-Met protein. C-Met encodes the hepatocyte growth factor receptor tyrosine kinase and plays an important role in tumor cell proliferation, survival, invasion, and metastasis, and tumor angiogenesis; this protein is overexpressed or mutated in a variety of cancers.
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    3-[(1S)-1-imidazo[1,2-a]pyridin-6-ylethyl]-5-(1-methylpyrazol-4-yl)triazolo[4,5-b]pyrazine
    2.1.2 InChI
    InChI=1S/C17H15N9/c1-11(12-3-4-15-18-5-6-25(15)10-12)26-17-16(22-23-26)19-8-14(21-17)13-7-20-24(2)9-13/h3-11H,1-2H3/t11-/m0/s1
    2.1.3 InChI Key
    XYDNMOZJKOGZLS-NSHDSACASA-N
    2.1.4 Canonical SMILES
    CC(C1=CN2C=CN=C2C=C1)N3C4=NC(=CN=C4N=N3)C5=CN(N=C5)C
    2.1.5 Isomeric SMILES
    C[C@@H](C1=CN2C=CN=C2C=C1)N3C4=NC(=CN=C4N=N3)C5=CN(N=C5)C
    2.2 Other Identifiers
    2.2.1 UNII
    2A2DA6857R
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1h-pyrazol-4-yl)-1h-(1,2,3)triazolo(4,5-b)pyrazine

    2. Azd6094

    3. Hmpl-504

    4. Volitinib

    2.3.2 Depositor-Supplied Synonyms

    1. Volitinib

    2. 1313725-88-0

    3. Azd-6094

    4. Hmpl-504

    5. Azd6094

    6. Savolitinib [inn]

    7. Hmpl504

    8. (s)-1-(1-(imidazo[1,2-a]pyridin-6-yl)ethyl)-6-(1-methyl-1h-pyrazol-4-yl)-1h-[1,2,3]triazolo[4,5-b]pyrazine

    9. Chembl3334567

    10. 2a2da6857r

    11. 1h-1,2,3-triazolo(4,5-b)pyrazine, 1-((1s)-1-imidazo(1,2-a)pyridin-6-ylethyl)-6-(1-methyl-1h-pyrazol-4-yl)-

    12. 3-[(1s)-1-imidazo[1,2-a]pyridin-6-ylethyl]-5-(1-methylpyrazol-4-yl)triazolo[4,5-b]pyrazine

    13. Orpathys

    14. Unii-2a2da6857r

    15. Azd6094, Hmpl-504

    16. Volitinib(savolitinib)

    17. Azd-6094volitinib

    18. Savolitinib (usan/inn)

    19. Savolitinib [usan:inn]

    20. Savolitinib [usan]

    21. Savolitinib [who-dd]

    22. Gtpl9918

    23. Hmpl 504

    24. Schembl12489208

    25. Ex-a845

    26. Dtxsid801111016

    27. Azd 6094

    28. Bdbm50023342

    29. Mfcd28359096

    30. Nsc782121

    31. Nsc800966

    32. S7674

    33. Akos030526403

    34. Savolitinib(azd6094, Hmpl-504)

    35. Zinc149738712

    36. Ccg-267976

    37. Db12048

    38. Nsc-782121

    39. Nsc-800966

    40. Compound 28 [pmid: 25148209]

    41. Ncgc00475727-01

    42. Ac-35267

    43. As-35250

    44. Bv160378

    45. Hy-15959

    46. Savolitinib;volitinib;hmpl-504;azd-6094

    47. A14419

    48. D11139

    49. J-690125

    50. Q27254463

    51. (3e)-5-chloro-3-[(5-{3-[(4-methyl-1,4-diazepan-1-yl)carbonyl]phenyl}-2-furyl)methylene]-1,3-dihydro-2h-indol-2-one Hydrochloride

    52. 1-((s)-1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1h-pyrazol-4-yl)-1h-(1,2,3)-triazolo(4,5-b)pyrazine

    53. 4-{1-[(1s)-1-{imidazo[1,2-a]pyridin-6-yl}ethyl]-1h-[1,2,3]triazolo[4,5-b]pyrazin-6-yl}-1-methyl-1h-pyrazole

    2.4 Create Date
    2012-11-30
    3 Chemical and Physical Properties
    Molecular Weight 345.4 g/mol
    Molecular Formula C17H15N9
    XLogP31.5
    Hydrogen Bond Donor Count0
    Hydrogen Bond Acceptor Count6
    Rotatable Bond Count3
    Exact Mass345.14504152 g/mol
    Monoisotopic Mass345.14504152 g/mol
    Topological Polar Surface Area91.6 Ų
    Heavy Atom Count26
    Formal Charge0
    Complexity505
    Isotope Atom Count0
    Defined Atom Stereocenter Count1
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Drug Indication

    Treatment of lung cancer

    Treatment of renal neoplasms